KOFI IES fegy a@
WY pt
510(k) Summary
ArthroCare Corporation
ArthroCare ArthroWands AUG - .
7 2007
General Information
Submitter Name/Address: ArthroCare Corporation
680 Vaqueros Avenue
Sunnyvale, CA 94085-3523
Establishment Registration Number: 295 1580
Contact Person: Valerie Defiesta-Ng
Director, Regulatory Affairs
Date Prepared: July 13, 2007
Device Description
Trade Name: ArthroCare® ArthroWands®
Generic/Common Name: Electrosurgical Device and Accessories
Classification Name: Electrosurgical Cutting and Coagulation
Device and Accessories (21 CFR 878.4400)
Predicate Devices
aredicate cevices
ArthroCare” ArthroWands® K070958
ArthroCare System K040338
Product Description
The ArthroCare ArthroWands are bipolar, single use, high frequency electrosurgical
devices designed for specific indications in arthroscopic and orthopedic procedures.
xii

Ko Ft { G63 p a Q 4h (3)
ee SE en.
Intended Uses
The ArthroCare ArthroWands are indicated for resection, ablation, and coagulation of
soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures:
Joint Specific or All
Arthroscopic and Orthopedic Procedures Joints (ankle, elbow,
hip, knee, shoulder, and
wrist)
xiii

Lo KOFI %
KOF! 763 p . 2 4, (3)
Continued
Joint Specific or All
. . Joints (ankle, elbow,
Arthroscopic and Orthopedic Procedures hip, knee, shoulder, and
wrist)
Substantial Equivalence
This Special 510(k) proposes modifications in the performance specifications and
labeling for the ArthroCare ArthroWands, which were previously cleared in KO70958
(April 23, 2007) and K040338 (March 1, 2004). The indications for use, technology,
principle of operation, and sterilization parameters of the ArthroCare ArthroWands
remain the same as in the predicate cleared 510(k)s.
Summary of Safety and Effectiveness
The modified ArthroCare ArthroWands, as described in this Special 510(k), are
substantially equivalent to the predicate device. The proposed modification in the
material is a not substantial change or modification, and does not significantly affect the
safety or efficacy of the devices.
xiv

: e DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
vom Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

ArthroCcare Corporation AUG - 7 2007
% Ms. Valerie DeFiesta-Ng
Director, Regulatory Affairs
680 Vaqueros Avenue
Sunnyvale, California 94085-3523
Re: K071963

Trade/Device Name: ArthroCare® ArthroWands®

Regulation Number: 21 CFR 878.4400

Regulation Name: Electrosurgical cutting and coagulation device and accessories

Regulatory Class: II

Product Code: GET

Dated: July 13, 2007

Received: July 16, 2007
Dear Ms. DeFiesta-Ng:
We have reviewed your Section $10(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class I] (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Ms. Valerie DeFiesta-Ng
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(240) 276-3150 or at its Internet address htip:/Avww.fda.gov/cdrh/industry/support/index.html.
| al, 7 Ai.

Mark N. Melkerson

Director

Division of General, Restorative

and Neurological Devices
Office of Device Evaluation
: Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement
510(k) Number: KO F/96ER
Device Name ArthroCare® ArthroWands® i? ge. t 4 @)
Indications for Use:
The ArthroCare ArthroWands are indicated for resection, ablation, and coagulation of
soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures:
| Soint Specific or AN
Arthroscopic-and Orthopedic Procedures”. | Joints (ankle, elbow,
“hip, Knee, shoulder, and
/
“4
’ \9
Ny
aN |
S IK Excision and Resection _
#¢)S
\ Zz
. = 2 \
ee ‘|e CapsularRelease CdS SCSC*CiWKinwes—
Ses .
BS 2
laas &
Bee =
rr Ae
3
ao es
x

Ko Fl 463 f- a 8 4@)
Continued
ee : Joint Specific or-All
2 fea _ Joints (ankle, elbow,
Arthroscopic and Orthopedic Procedures hip, knee, shoulder, and
; woe ee wrist)
* Triangular Fibrocartilage (TFCC)
Coagulation
¢  Glenohumeral Capsule
Prescription Use xX AND/OR — Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of General, Resterative,
and Neurological Devices , 9 £ 3
510(k) Number Kote
: xi

